NASD · Healthcare · Biotechnology · USA
Arcutis Biotherapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company that develops and commercializes treatments for dermatological diseases. The company markets ZORYVE, a topical and systemic treatment for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, available in the United States and Canada. Arcutis also has ARQ-234, a checkpoint agonist in development for atopic dermatitis and other inflammatory conditions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Arcutis Biotherapeutics Inc stock.
Fairly valued: intrinsic value $28.16 per share, market price $27.33, margin of safety 3.0% (as of 2026-11-17).
A 7.1x revenue multiple, discounted for its losses, values the shares at $28.16; the price of $27.33 is 3% below that value.
17 more funds hold it; the full list is part of the paid plan.
20 more in this industry show a wider margin of safety.
ARQT is fairly valued (as of the 2026-11-17 close). A 7.1x revenue multiple, discounted for its losses, values the shares at $28.16; the price of $27.33 is 3% below that value.
$28.16 per share (as of the 2026-11-17 close), against a market price of $27.33. That is a margin of safety of 3.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.